IFN-γ controls the generation/activation of CD4+CD25 + regulatory T cells in antitumor immune response

Journal of Immunology

Volumn 175, Issue 7, 2005, Pages 4433-4440

  Nishikawa, Hiroyoshi ^a,c   Kato, Takuma ^a   Tawara, Isao ^a   Ikeda, Hiroaki ^a,b,d   Kuribayashi, Kagemasa ^a   Allen, Paul M ^b   Schreiber, Robert D ^b   Old, Lloyd J ^c   Shiku, Hiroshi ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; LUNG METASTASIS; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROLOGY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

EID: 25444439253     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.7.4433     Document Type: Article

References (53)

1. Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh, and M. Toda. 1995. Immunologic self-tolerance maintained by activated T. cells expressing IL-2 receptor α-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155: 1151-1164.
2. Maloy, K. J., and F. Powrie. 2001. Regulatory T cells in the control of immune pathology. Nat. Immunol. 2: 816-822.
3. + suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2: 389-400.
4. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22: 531-562.
5. + regulatory T cells induced by an agonist self-peptide. Nat. Immunol. 2: 301-306.
6. Apostolou, I., A. Sarukhan, L. Klein, and H. von Boehmer. 2002. Origin of regulatory T cells with known specificity for antigen. Nat. Immunol. 3: 756-763.
7. Anderson, A. C., and V. K. Kuchroo. 2003. Expression of self-antigen in the thymus: a little goes a long way. J. Exp. Med. 198: 1627-1629.
8. van Santen, H. M., C. Benoist, and D. Mathis. 2004. Number of T reg cells that differentiate does not increase upon encounter of agonist ligand on thymic epithelial cells. J. Exp. Med. 200: 1221-1230.
9. Nishikawa, H., K. Tanida, H. Ikeda, M. Sakakura, Y. Miyahara, T. Aota, K. Mukai, M. Watanabe, K. Kuribayashi, L. J. Old, and H. Shiku. 2001. Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity. Proc. Natl. Acad. Sci. USA 98: 14571-14576.
10. + T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc. Natl. Acad. Sci. USA 100: 10902-10906.
11. + regulatory T cells. J. Exp. Med. 201: 681-686.
12. + regulatory T cells in wild-type hosts. Proc. Natl. Acad. Sci. USA 102: 9253-9257.
13. Sahin, U., O. Tureci, H. Schmitt, B. Cochlovius, T. Johannes, R. Schmits, F. Stenner, G. Luo, I. Schobert, and M. Pfreundschuh. 1995. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA 92: 11810-11813.
14. Chen, Y.-T., M. J. Scanlan, Y. Obata, and L. J. Old. 2000. Identification of human tumor antigens by serological expression cloning (SEREX). In Principles and Practice of the Biologic Therapy of Cancer. Lippincott, Williams & Wilkins, Philadelphia, pp. 557-570.
15. Ikeda, H., N. Ohta, K. Furukawa, H. Miyazaki, L. Wang, K. Kuribayashi, L. J. Old, and H. Shiku. 1997. Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma. Proc. Natl. Acad. Sci. USA 94: 6375-6379.
16. + T cell adoptive immunotherapy. Immunity 13: 265-276.
17. lo thymocytes in vivo. Science 250: 1720-1723.
18. DeLeo, A. B., H. Shiku, T. Takahashi, M. John, and L. J. Old. 1977. Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma. J. Exp. Med. 146: 720-734.
19. Van Pel, A., E. De Plaen, and T. Boon. 1985. Selection of highly transferable variant from mouse mastocytoma P815. Somat. Cell. Mol. Genet. 11: 467-475.
20. Nagata, Y., R. Furugen, A. Hiasa, H. Ikeda, N. Ohta, K. Furukawa, H. Nakamura, T. Kanematsu, and H. Shiku. 1997. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J. Immunol. 159: 1336-1343.
21. Niwa, H., K. Yamamura, and J. Miyazaki. 1991. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108: 193-199.
22. Cui, J., T. Shin, T. Kawano, H. Sato, E. Kondo, I. Toura, Y. Kaneko, H. Koseki, M. Kanno, and M. Taniguchi. 1997. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 278: 1623-1626.
23. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061.
24. Zelenika, D., E. Adams, S. Humm, L. Graca, S. Thompson, S. P. Cobbold, and H. Waldmann. 2002. Regulatory T cells overexpress a subset of Th2 gene transcripts. J. Immunol. 168: 1069-1079.
25. + cells contribute to Th2 polarization during helminth infection by suppressing Th1 response development. J. Immunol. 173: 1224-1231.
26. + regulatory T cells by antigen-processing dendritic cells. J. Exp. Med. 198: 235-247.
27. + regulatory T cells control T helper cell type 1 responses to foreign antigens induced by mature dendritic cells in vivo. J. Exp. Med. 198: 259-266.
28. Uchijima, M., T. Nagata, T. Aoshi, and Y. Koide. 2005. IFN-γ overcomes low responsiveness of myeloid dendritic cells to CpG DNA. Immunol. Cell. Biol. 83: 92-95.
29. + T cell-mediated suppression by dendritic cells. Science 299: 1033-1036.
30. Yang, Y., C. T. Huang, X. Huang, and D. M. Pardoll. 2004. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol. 5: 508-515.
31. Ulloa, L., J. Doody, and J. Massague. 1999. Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway. Nature 397: 710-713.
32. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. 198: 1875-1886.
33. - T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol 172: 5149-5153.
34. + regulatory T cells. J. Exp. Med. 201: 737-746.
35. + regulatory T cells. J. Exp. Med. 201: 1061-1067.
36. Sawitzki, B., C. I. Kingsley, V. Oliveira, M. Karim, M. Herber, and K. J. Wood. 2005. IFN-γ production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo. J. Exp. Med. 201: 1925-1935.
37. + regulatory T cells. Nat. Immunol. 4: 330-336.
38. + T regulatory cells. Nat. Immunol. 4: 337-342.
39. Farrar, M. A., and R. D. Schreiber. 1993. The molecular cell biology of interferon-γ and its receptor. Annu. Rev. Immunol. 11: 571-611.
40. Boehm, U., T. Klamp, M. Groot, and J. C. Howard. 1997. Cellular responses to interferon-γ. Annu. Rev. Immunol. 15: 749-795.
41. Ikeda, H., L. J. Old, and R. D. Schreiber. 2002. The roles of IFN γ in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 13: 95-109.
42. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3: 133-146.
43. Coulie, P. G., V. Brichard, A. Van Pel, T. Wolfel, J. Schneider, C. Traversait S. Mattel, E. De Plaen, C. Lurquin, J. P. Szikora, et al. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180: 35-42.
44. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, L. Rivoltini, S. L. Topalian, T. Miki, and S. A. Rosenberg. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91: 3515-3519.
45. Chen, Y.-T., M. J. Scanlan, U. Sahin, O. Tureci, A. O. Gure, S. Tsang, B. Williamson, E. Stockert, M. Pfreundschuh, and L. J. Old. 1997. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 94: 1914-1918.
46. Jager, E., Y.-T. Chen, J. W. Drijfhout, J. Karbach, M. Ringhoffer, D. Jager, M. Arand, H. Wada, Y. Noguchi, E. Stocken, et al. 1998. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187: 265-270.
47. Tsomides, T. J., E. B. Reilly, and H. N. Eisen. 1997. Anti-melanoma cytotoxic T lymphocytes (CTL) recognize numerous antigenic peptides having 'self' sequences: autoimmune nature of the anti-melanoma CTL response. Int. Immunol. 9: 327-338.
48. + cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. J. Exp. Med. 195: 113-123.
49. Pamer, E. G., A. J. Sijts, M. S. Villanueva, D. H. Busch, and S. Vijh. 1997. MHC class I antigen processing of Listeria monocytogenes proteins: implications for dominant and subdominant CTL responses. Immunol. Rev. 158: 129-136.
50. Boon, T., and L. J. Old. 1997. Cancer tumor antigens. Curr. Opin. Immunol. 9: 681-683.
51. Scanlan, M. J., A. O. Gure, A. A. Jungbluth, L. J. Old, and Y.-T. Chen. 2002. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 188: 22-32.
52. Dudley, M. E., and S. A. Rosenberg. 2003. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer 3: 666-675.
53. Jager, E., D. Jager, and A. Knuth. 2003. Antigen-specific immunotherapy and cancer vaccines. Int. J. Cancer 106: 817-820.